The Oral Overnight Metyrapone Test

Differentiating thyrotoxicosis etiologies requires moving beyond suppressed TSH to evaluate free T3 to free T4 ratios, TRAb titers, and radioactive iodine uptake kinetics. We break down distinguishing high-uptake states like Graves disease and toxic adenomas from destructive thyroiditis, the utility of Doppler ultrasound, and targeted management strategies across antithyroid drug selection, radioactive iodine, and surgical indications.

The overnight metyrapone test interrogates hypothalamic-pituitary-adrenal reserve via 11-beta-hydroxylase blockade, circumventing cosyntropin false-negatives in acute corticotroph injury where adrenocortical atrophy is absent. Interpretation demands sequential analysis: post-dose cortisol below 5 ug/dL confirms enzyme inhibition, while 11-deoxycortisol above 7 ug/dL verifies reserve. Levels between 7 to 10 ug/dL require Bayesian pretest calibration. Testing established insufficiency risks precipitating adrenal crisis.

Radioactive iodine uptake differentiates de novo hyperthyroidism from destructive or factitious thyrotoxicosis. Diffusely elevated tracer accumulation confirms Graves disease driven by thyrotropin-receptor antibodies, whereas focal autonomy denotes toxic adenoma or toxic multinodular goiter with extranodular suppression. Conversely, suppressed or absent uptake indicates destructive thyroiditis, exogenous hormone exposure, or recent iodine contamination, shifting clinical management from thionamides toward symptomatic beta-blockade.

This episode reviews the differential diagnosis of paroxysmal adrenergic symptoms, contrasting sympathoadrenal hyperreactivity with catecholamine-secreting neuroendocrine tumors. We analyze the diagnostic utility and pre-test confounding factors of plasma versus fractionated urinary metanephrines, evaluate concurrent features of thyrotoxicosis, carcinoid syndrome, and mast cell activation, and outline evidence-based alpha-blockade protocols prior to surgical or medical intervention.

This episode evaluates postural orthostatic tachycardia syndrome, exploring neuroendocrine and autonomic dysregulation, including hyperadrenergic phenotypes and volume depletion. We examine diagnostic tilt-table criteria, the crucial exclusion of primary endocrine mimics such as pheochromocytoma and adrenal insufficiency, and evidence-based management strategies spanning fludrocortisone, nonselective beta-blockers, alpha-1 agonists, and structured physical reconditioning.

This episode examines subclinical hyperthyroidism, characterized by suppressed serum TSH alongside normal free thyroxine and triiodothyronine. We analyze etiology differentiation between autonomous nodular disease and Graves disease, risk stratification for atrial fibrillation and accelerated bone loss, and guideline thresholds for initiating antithyroid pharmacotherapy or definitive ablation in older adults and postmenopausal patients.

Pretest probability dictates the entire diagnostic workflow for Cushing syndrome by guiding appropriate patient selection for screening and preventing false positives from incidentalomas or physiological hypercortisolism. Because diagnostic tests carry distinct false-positive rates when applied to low-risk populations, initial biochemical evaluation must be strictly reserved for patients with recognizable clinical stigmata or progressive multisystem manifestations. Quantifying clinical probability prevents the diagnostic cascade of unindicated testing, ensuring that abnormal screening results reflect true autonomous cortisol excess rather than benign physiological mimics or stress-induced alterations.

Screening for primary aldosteronism requires measuring the aldosterone-to-renin ratio under standardized conditions, accounting for interfering antihypertensives and hypokalemia. Diagnosis hinges on non-suppressible autonomous aldosterone secretion via confirmatory suppression testing. Once confirmed, adrenal protocol cross-sectional imaging and adrenal vein sampling are essential to reliably differentiate unilateral surgically curable adenomas from bilateral idiopathic adrenal hyperplasia prior to targeted intervention.

Familial partial lipodystrophy mutations causing progressive subcutaneous fat loss from the extremities and trunk with paradoxical fat accumulation in the face and neck. This redistribution precipitates severe insulin resistance, hypertriglyceridemia, and premature cardiovascular disease. Diagnosis relies on physical examination recognizing characteristic fat loss patterns, genetic testing, and metabolic profiling. Management focuses on aggressive metabolic optimization, lifestyle modification, and targeted therapies for dyslipidemia and glycemic control to mitigate long-term cardiovascular and hepatic sequelae.

Emil Theodor Kocher revolutionized endocrine surgery by developing meticulous, sterile, and bloodless thyroidectomy techniques. His standardized operative methods reduced surgical mortality from nearly forty percent to under one percent. Kocher's precise documentation of cachexia strumipriva fundamentally delineated thyroid physiological function and postoperative myxedema, establishing the foundations of modern surgical endocrinology and safe neck exploration.